X

Trial Profile

Randomized Phase II Study of Weekly ABI-007 Plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Gemcitabine
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use
Acronyms AFUGEM

Most Recent Events

30 Jan 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
30 Jan 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2017.
10 Aug 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com